Glucocorticosteroids associated with a decreased risk of psychosis

Journal of Clinical Psychopharmacology

Volumn 29, Issue 3, 2009, Pages 288-290

  Laan, Wijnand ^a   Smeets, Hugo ^a   De Wit, Niek J ^a   Kahn, René S ^b   Grobbee, Diederick E ^a   Burger, Huibert ^a,c  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Glucocorticosteroids; Inflammation; Psychosis; Schizophrenia

Indexed keywords

GLUCOCORTICOID;

ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MENTAL FUNCTION; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; SCHIZOPHRENIA; SEX DIFFERENCE;

ADMINISTRATION, INHALATION; ADULT; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; CHRONIC DISEASE; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MALE; ODDS RATIO; PSYCHOTIC DISORDERS; SEX FACTORS;

EID: 67649265238     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181a44575     Document Type: Article

References (12)

1. Freedman R. Schizophrenia. N Engl J Med. 2003;349(18):1738-1749.
2. Wiersma D, Nienhuis FJ, Slooff CJ, et al. Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull. 1998;24(1):75-85.
3. Laan W, Selten JP, Grobbee DE, et al. Non-steroidal anti-inflammatory drugs and the risk of psychosis. Eur Neuropsychopharmacol. 2007;17(4):309-311.
4. Akhondzadeh S, Tabatabaee M, Amini H, et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res. 2007;90(1-3):179-185.
5. Müller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159(6):1029-1034.
6. Potvin S, Stip E, Sepehry AA, et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry. 2008;63(8):801-808.
7. Yilmaz N, Herken H, Cicek HK, et al. Increased levels of nitric oxide, cortisol and adrenomedullin in patients with chronic schizophrenia. Med Princ Pract. 2007;16(2):137-141.
8. Riad M, Mogos M, Thangathurai D, et al. Steroids. Curr Opin Crit Care. 2002;8(4):281-284.
9. van Haren NE, Hulshoff Pol HE, Schnack HG, et al. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol Psychiatry. 2008;63(1):106-113.
10. Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol. 2001;51(5):400-409.
11. Sirois F. Steroid psychosis: a review. Gen Hosp Psychiatry. 2003;25(1):27-33.
12. Riecher-Rössler A. Oestrogen effects in schizophrenia and their potential therapeutic implications - Review. Arch Women Mental Health. 2002;5(3):111-118.